Studied in adults with treatment-resistant depression and taken with a daily oral antidepressant
Greater reduction of depressive symptoms at four weeks‡ (compared to those who received a placebo and oral antidepressant)
Nasal spray you self-administer under the supervision of a healthcare professional
In clinical trials, after 16 weeks of therapy, patients who stayed on SPRAVATO®† were less likely to experience a return of depressive symptoms than those who stopped therapy
After you take SPRAVATO®, a healthcare provider will monitor you for at least two hours during the observation period for possible serious side effects